This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Custopharm parent agrees to divest steroid drug to resolve US FTC concerns with Hikma deal

( April 19, 2022, 16:57 GMT | Official Statement) -- MLex Summary: Custopharm’s parent company has agreed to transfer Custopharm’s assets related to the corticosteroid drug triamcinolone acetonide, or TCA, to its Long Grove Pharmaceuticals subsidiary. With the divestiture, the US Federal Trade Commission will let Hikma’s acquisition of Custopharm go through. “Hikma’s acquisition of Custopharm’s TCA business could have caused significant harm for patients who use TCA to treat severe skin conditions, allergies, and inflammation,” said Holly Vedova, director of the FTC’s Bureau of Competition. “The FTC’s action ensures that Hikma still has the incentive to bring its TCA product to market, which will benefit consumers.”See statement in full. See documents attached....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login